Translate page

-- Virtual Education Program: 2019 Edition

 

Presentations from the COLT Meeting 2019

We are pleased to make available a series of presentations from the COLT Meeting 2019, a CML Opinion Leader Training that took place in Adelaide (Australia). Topics cover; CML therapy - state of science, management of CML, practicalities and monitoring TFR and Ph+ALL.


Timothy Hughes

David Yeung 3 Devendra Hiwase

Session 1: CML therapy - state of science
Chair: Prof. Tim Hughes

  • Frontline Therapy for CML 
    (Prof Tim Hughes)
  • When frontline therapy fails
    (Dr David Yeung)
  • CML - Beyond chronic phase
    (Dr Devendra Hiwase)

 

 

Naranie

David Yeung 3 Susan Branford                    

Session 2: CML Management, Practicalities
Chair: Dr David Yeung

  • Managing TKI toxicities
    (Dr Naranie Shanmuganathan)
  • Allograft - still a role in CML?
    (Dr David Yeung)
  • Molecular monitoring
    (A/Prof Susan Branford)

 

 

Susan Branford

 

David Yeung 3                  

 

Session 3: Monitoring TFR and Ph+ ALL
Chair: Dr Naranie Shanmunagathan

  • Monitoring TFR - Challenges 
    (A/Prof Susan Branford)
  • Ph+ ALL
    (Dr David Yeung)

 

Presentations from the 24rd Congress of EHA 

We are pleased to make available a couple of presentations on various aspects of CML management that were first presented at the 24rd Congress of the European Hematology Association in Amsterdam. Presentations include; CML treatment in the era of operational cure: considerations for therapy selection; current treatment approaches in CML, The future of CML therapy: unmet medical needs and new treatments in development, TKI safety and special aspects in children. 

Michael Mauro EHA 2019

 

The Future of CML Therapy: Unmet Medical Needs and New Treatments in Development
Professor Michael Mauro, Memorial Sloan Kettering Cancer Center New York, USA 

  • Unmet needs in CML: TKI and SCT
  • TKI's in development for CML
  • Development of Asciminib for CML
  • ABL 001X2101: A multicenter, phase 1, first-in-human study
    •  Allosteric inhibition of BCR-ABL
    •  ABL 001X2201: T315l cohort
    • Asciminib phase 3 study Design NCT 03106779
    • Asciminib Phase 2 study design:
      Add-on to first-line imatinib for DMR NCT 03578367
  • PF-114: 3rd generation BCR-ABL
 

This talk was first presented at EHA during the Satellite Symposium: 'Optimizing patient outcomes in CML and classical MPN's: New treatment paradigms and future developments' - supported by Incyte. You will find more education materials from EHA at the EHA Learning Centre

Rosti EHA 2019


Current Treatment Approaches in CML
Professor Gianantonio Rosti, University of Bologna, Italy 

  • The natural course of CML
  • A conceptional model for progression for CML
  • The weight of the choice of 1st line treatment:
    2014 vs. 2019
  • Finding the track for 1st line TKI
    • Reaching earlier milestones of response
    • The disease risk
    • Is the patient 'eligible' for treatment discontinuation?
  • Facing a treatment failure
  • Take home messages

 

 

 

This talk was first presented during the Education Session on Chronic Myeloid Leukemia at EHA. You will find more education materials from EHA at the EHA Learning Centre